ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R)
August 29, 2017TAIPEI, Taiwan, China and CINCINNATI, Aug. 28, 2017 /PRNewswire/ -- Lumosa Therapeutics Co., Ltd. ("Lumosa"), a Taipei-based biopharmaceutical company developing innovative therapies focused on the treatment of neurological and inflammatory disease -
Enrollment of first human subject for Lumosa Therapeutics’ LT3001 trial
August 15, 2017The first human subject was dosed with LT3001 in California, USA on 28 July 2017, with the trial to evaluate the safety and pharmacokinetics of LT3001 expected to be completed in early 2018.
Pharma Sources Insight January 2025
